Savara shares fell 16% in premarket trading on Friday after the United States Food and Drug Administration missed its November 22 deadline to decide on the company's rare lung disease treatment. The missed decision delivers a setback to the biotech firm as it awaits word on its experimental drug. Investors face an extended wait for regulatory clarity with no new decision date provided.

Review Remains Underway